Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir
Peter A C Wing, Meleri Jones, Michelle Cheung, Sampath DaSilva, Connor Bamford, Wing-Yiu Jason Lee, Elihu Aranday-Cortes, Ana Da Silva Filipe, John McLauchlan, David Smith, William Irving, Morven Cunningham, Azim Ansari, Eleanor Barnes, Graham R Foster, Peter A C Wing, Meleri Jones, Michelle Cheung, Sampath DaSilva, Connor Bamford, Wing-Yiu Jason Lee, Elihu Aranday-Cortes, Ana Da Silva Filipe, John McLauchlan, David Smith, William Irving, Morven Cunningham, Azim Ansari, Eleanor Barnes, Graham R Foster
Abstract
Background & aims: Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections, and resistance-associated substitutions in the polymerase are rare. However, HCV genotype 3 responds slightly less well to sofosbuvir-based therapies than other genotypes. We collected data from England's National Health Service Early Access Program to search for virus factors associated with sofosbuvir treatment failure.
Methods: We collected patient serum samples and used the capture-fusion assay to assess viral sensitivity to sofosbuvir in 14 HCV genotype 3 samples. We identified polymorphisms associated with reduced response and created modified forms of HCV and replicons containing the substitutions of interest and tested their sensitivity to sofosbuvir and ribavirin. We examined the effects of these polymorphisms by performing logistic regression multivariate analysis on their association with sustained virologic response in a separate cohort of 411 patients with chronic HCV genotype 3 infection who had been treated with sofosbuvir and ribavirin, with or without pegylated interferon.
Results: We identified a substitution in the HCV genotype 3a NS5b polymerase at amino acid 150 (alanine [A] to valine [V]), V at position 150 was observed in 42% of patients) with a reduced response to sofosbuvir in virus replication assays. In patients treated with sofosbuvir-containing regimens, the A150V variant was associated with a reduced response to treatment with sofosbuvir and ribavirin, with or without pegylated interferon. In 326 patients with V at position 150, 71% achieved an sustained virologic response compared to 88% with A at position 150. In cells, V at position 150 reduced the response to sofosbuvir 7-fold. We found that another rare substitution, glutamic acid (E) at position 206, significantly reduced the response to sofosbuvir (8.34-fold reduction); the combinations of V at position 150 and E at position 206 reduced the virus response to sofosbuvir 35.77-fold. Additionally, in a single patient, we identified 5 rare polymorphisms that reduced sensitivity to sofosbuvir our cell system.
Conclusions: A common polymorphism, V at position 150 in the HCV genotype 3a NS5b polymerase, combined with other variants, reduces the virus response to sofosbuvir. Clinically, infection with HCV genotype 3 containing this variant reduces odds of sustained virologic response. In addition, we identified rare combinations of variants in HCV genotype 3 that reduce response to sofosbuvir.
Keywords: amino acid change; genetics; mutation; response to therapy.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Figures
References
- Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther. 2013;11:1269–1279.
- Gane E.J., Stedman C.A., Hyland R.H. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.
- Afdhal N., Zeuzem S., Kwo P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
- Buti M., Calleja J.L., Lens S. Simeprevir in combination with sofosbuvir in treatment-naive and -experienced patients with hepatitis C virus genotype 4 infection: a phase III, open-label, single-arm study (PLUTO) Aliment Pharmacol Ther. 2017;45:468–475.
- Donaldson E.F., Harrington P.R., O'Rear J.J. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61:56–65.
- Gane E.J., Shiffman M.L., Etzkorn K. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017
- Jacobson I.M., Lawitz E., Gane E.J. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic hcv infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
- Bourliere M., Gordon S.C., Flamm S.L. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–2146.
- Foster G.R., Afdhal N., Roberts S.K. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
- Petruzziello A., Marigliano S., Loquercio G. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840.
- D'Souza R., Glynn M.J., Ushiro-Lumb I. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol. 2005;3:910–917.
- Shoeb D., Rowe I.A., Freshwater D. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol. 2011;23:747–753.
- Xu S., Doehle B., Rajyaguru S. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antivir Ther. 2017;22:587–597.
- Fourati S., Rodriguez C., Hezode C. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology. 2019;69:513–523.
- Svarovskaia E.S., Dvory-Sobol H., Parkin N. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–1674.
- Zeuzem S., Mizokami M., Pianko S. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–918.
- Cheung M.C., Walker A.J., Hudson B.E. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741–747.
- Foster G.R., Irving W.L., Cheung M.C. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
- Cunningham M.E., Javaid A., Waters J. Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology. 2015;61:1192–1204.
- Lontok E., Harrington P., Howe A. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.
- Singer J.B., McLauchlan J., Hughes J., Gifford R.J. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics. 2018;19:532.
- Foster G.R., Pianko S., Brown A. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis c virus genotype 2 infection. Gastroenterology. 2015;149:1462–1470.
- Appleby T.C., Perry J.K., Murakami E. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science. 2015;347:771–775.
- Hagedorn C.H. Hepatitis C Virus RNA-dependent RNA polymerase (NS5B Polymerase) Methods Mol Med. 1999;19:365–372.
- Waheed Y., Saeed U., Anjum S. Development of global consensus sequence and analysis of highly conserved domains of the HCV NS5B protein. Hepat Mon. 2012;12(9)
- Qin W., Yamashita T., Shirota Y. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology. 2001;33:728–737.
- Shirota Y., Luo H., Qin W. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem. 2002;277:11149–11155.
- Shimakami T., Hijikata M., Luo H. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol. 2004;78:2738–2748.
- te Velthuis A.J. Common and unique features of viral RNA-dependent polymerases. Cell Mol Life Sci. 2014;71:4403–4420.
- Saeed M., Scheel T.K.H., Gottwein J.M. Efficient replication of genotype 3a and 4a hepatitis c virus replicons in human hepatoma cells. Antimicrob Agents Chemother. 2012;56:5365–5373.
- Ramirez S., Mikkelsen L.S., Gottwein J.M. Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir. Gastroenterology. 2016;151:973–985 e2.
- Sheldon J., Beach N.M., Moreno E. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol. 2014;88:12098–12111.
- Zeuzem S., Foster G.R., Wang S. Glecaprevir-pibrentasvir for 8 or 12 weeks in hcv genotype 1 or 3 infection. N Engl J Med. 2018;378:354–369.
- Svarovskaia E.S., Gane E., Dvory-Sobol H. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis. 2016;213:1240–1247.
- Kowdley K.V., Gordon S.C., Reddy K.R. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
- Sarrazin C., Dvory-Sobol H., Svarovskaia E.S. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–512 e1.
- Cunningham M.E., Javaid A., Waters J. Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology. 2015;61:1192–1204.
- Sheldon J., Beach N.M., Moreno E. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol. 2014;88:12098–12111.
Source: PubMed